

# Toripalimab with chemotherapy for untreated advanced oesophageal squamous cell cancer (terminated appraisal)

Technology appraisal guidance

Published: 11 December 2024

[www.nice.org.uk/guidance/ta1024](https://www.nice.org.uk/guidance/ta1024)

# Contents

Advice.....	3
Information.....	3

## Advice

NICE is unable, at this time, to make a recommendation about the use in the NHS of toripalimab with chemotherapy for untreated advanced oesophageal squamous cell cancer in adults. This is because Shanghai Junshi Bioscience has requested a delay to the evidence submission.

## Information

If NHS organisations wish to consider toripalimab for this indication, they should follow the advice on rational local decision making in the [NHS Constitution for England](#) and the [NHS Commissioning Board and Clinical Commissioning Groups \(Responsibilities and Standing Rules\) Regulations 2012](#). This outlines the approach that should be taken when there is no NICE guidance.

NICE will review the position when the company makes an evidence submission.

ISBN: 978-1-4731-6669-1